Cagrilintide for Health & Longevity
Evidence Review created on 10/30/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: AM833, NNC0174-0833
Motivation
Cagrilintide is an experimental, once-weekly injection that copies amylin, a hormone the pancreas releases together with insulin after a meal. Amylin tells the brain that a meal is over and slows the speed at which food leaves the stomach. Cagrilintide was built to last about a week in the body, which makes it a candidate drug for long-term weight control and blood sugar control.
Cagrilintide is being developed by its manufacturer both on its own and paired with semaglutide, the active ingredient of Wegovy. It drew attention because it works through a different appetite pathway than the popular weight-loss injections, and because some users of those injections stop them for stomach side effects. It is not approved anywhere, yet it is already sold online as a “research peptide” to people pursuing weight loss and healthy aging.
This review examines what the human trials of cagrilintide on its own show about weight, blood pressure, blood sugar and safety, what remains theory, and how these findings apply to health-focused adults who are weighing its use.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
High-level discussions of cagrilintide and the amylin drug class from expert and academic sources.
-
#387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field - Peter Attia
Appraises cagrilintide as one of several online “research peptides”: mechanism, trial weight loss, and the case for waiting for the regulated product rather than self-sourcing.
-
Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials - Alhazmi & le Roux, 2026
Up-to-date narrative review placing cagrilintide among newer amylin drugs, covering monotherapy weight loss, tolerability and the unproven bone effect. The senior author advises Novo Nordisk.
-
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity - D’Ascanio et al., 2024
Narrative review dedicated to cagrilintide: amylin physiology, how the molecule was engineered for weekly dosing, and the early human trials alone and with semaglutide.
Only three items qualify: no further expert or academic source discusses cagrilintide in depth without duplicating a source already listed. Life Extension’s Weight Management protocol mentions cagrilintide only in two short paragraphs within a broad weight-management page, so it was not included. Andrew Huberman, Chris Kresser and Lifespan.io have published no content on cagrilintide or amylin drugs that their site searches or web searches could find. Rhonda Patrick’s site returns cagrilintide only within episodes focused on GLP-1 (glucagon-like peptide-1, a gut hormone that curbs appetite and raises insulin) drugs and a members-only compilation, none of which discusses cagrilintide on its public pages.
Grokipedia
No Grokipedia article dedicated to cagrilintide as a single agent exists; the site covers it only within articles on its combination with semaglutide and on amylin generally.
Examine
No Examine article on cagrilintide exists. Examine.com does not typically cover prescription or investigational drugs, and cagrilintide is an unapproved investigational drug.
ConsumerLab
No ConsumerLab article on cagrilintide exists. ConsumerLab does not typically cover prescription or investigational drugs, and cagrilintide is an unapproved investigational drug that is not sold as a dietary supplement.
Systematic Reviews
Systematic reviews and meta-analyses that report results for cagrilintide on its own.
-
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. - Rao et al., 2026
Pools placebo-controlled trials: cagrilintide alone reduced weight by 6.08 percentage points more than placebo, with modest blood pressure effects and no significant glucose effect.
-
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. - Ahmed et al., 2026
Cagrilintide alone matched semaglutide’s weight loss but had more serious adverse events (risk ratio, the ratio of event rates, 1.83): the main monotherapy safety signal.
-
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. - Dutta et al., 2024
First meta-analysis of cagrilintide: weight loss similar to semaglutide or liraglutide, with significantly less vomiting; based on three small trials.
-
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. - Hamarsheh et al., 2026
Network meta-analysis (indirect comparison of many drugs) of 25 trials ranking cagrilintide against semaglutide, tirzepatide and CagriSema for weight loss and gastrointestinal adverse events.
-
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. - Kamrul-Hasan et al., 2026
Network meta-analysis of six amylin-drug trials: higher-dose cagrilintide beat placebo for weight loss and, like CagriSema, significantly increased constipation.
No systematic review or meta-analysis covers cardiovascular events, mortality or other hard clinical outcomes for cagrilintide, so the benefit that more established drugs have shown on such outcomes is unrepresented here.
Mechanism of Action
Cagrilintide is a modified form of amylin, a 37-amino-acid pancreatic hormone released with insulin after meals (Kruse 2021, by developer Novo Nordisk, which has a financial stake and produced most data cited here). Natural amylin clumps into fibrils and lasts minutes; amino-acid changes keep cagrilintide soluble, and a fatty-acid side chain (lipidation, attachment of a fat molecule) binds blood albumin, slowing clearance.
- Receptors: Cagrilintide activates amylin receptors AMY1, AMY2 and AMY3 (each a calcitonin receptor, the docking site of calcitonin, a bone-protecting thyroid hormone, paired with a modifying protein) and the calcitonin receptor alone: a dual amylin and calcitonin receptor agonist (activator), or DACRA (Fletcher 2021).
- Brain action: It acts in the area postrema (a hindbrain region outside the blood–brain barrier) and linked appetite centres; in mice its weight effect depends on AMY1 and AMY3 receptors (Carvas 2025).
- Gut and glucose: Like amylin, it slows gastric emptying (stomach emptying into the intestine) and suppresses post-meal glucagon (a hormone that raises blood sugar) (review: Alhazmi 2026).
- Pharmacology: Half-life 159–195 hours, peak blood level 24–72 hours after injection (Enebo 2021). As a peptide it is broken down by protein-cleaving enzymes, not cytochrome P450 (CYP) liver enzymes; severe kidney or liver impairment did not change exposure (Nielsen 2026).
Views on the calcitonin component compete: lab data suggest its activation may add weight loss (Fletcher 2021) and possibly protect bone, whereas selective amylin agonists (SARAs) spare it; clinical relevance remains unclear (review: Alhazmi 2026).
Historical Context & Evolution
Amylin was discovered in 1986 as the main component of the amyloid deposits (clumped protein deposits) found in the pancreas of people with type 2 diabetes, as a historical review recounts (Lutz 2022). Research soon showed that it is also a circulating hormone that curbs eating, slows stomach emptying and suppresses glucagon.
Because human amylin clumps, the first drug, pramlintide (Symlin), carried amino-acid substitutions that prevent clumping. It was approved in the United States in 2005 as an add-on to mealtime insulin for type 1 and type 2 diabetes (pramlintide FDA label). Its short half-life required injections before each meal, and it produced only modest weight loss, so interest faded as GLP-1 drugs took over (review: Secher 2026).
Novo Nordisk designed cagrilintide in the 2010s as a stable, once-weekly amylin analogue (Kruse 2021). A 2019 dose-finding trial showed weight loss with cagrilintide alone (Lau 2021); later trials paired it with semaglutide. The combination became the company’s lead programme and was submitted to the U.S. Food and Drug Administration in December 2025 (Novo Nordisk press release). After a 2025 analysis showed about 12% weight loss with cagrilintide alone, Novo Nordisk started a separate monotherapy phase 3 programme (Novo Nordisk press release, reprinted by Drugs.com).
Interest from health-optimization communities arose because cagrilintide uses an appetite pathway distinct from GLP-1 drugs and appears to cause less vomiting. That interest rests on weight and risk-factor data, not on any aging or survival outcome.
Expected Benefits
Nearly all human evidence comes from trials funded by Novo Nordisk, the drug’s developer, which has a direct financial interest in its adoption. No trial has measured disease events, frailty or survival with cagrilintide alone.
High 🟩 🟩 🟩
Body-Weight and Waist Reduction
Cagrilintide alone reduces body weight and waist size in adults with overweight or obesity, mainly by earlier meal termination. Placebo-controlled trials led by Lau (dose-finding, 706 adults, 26 weeks; Lau 2021, Novo Nordisk-funded) and Garvey (68 weeks; Garvey 2025), and a diabetes trial led by Frias (Frias 2023), all show loss; an independent meta-analysis confirms it (Rao 2026). For lean, already-healthy adults no trial exists.
Magnitude: Pooled across placebo-controlled trials, 6.08 percentage points more weight loss than placebo (95% CI, the range likely to contain the true effect, 4.14 to 8.02) (Rao 2026).
Medium 🟩 🟩
Blood-Pressure Lowering
In the 68-week REDEFINE 1 trial, cagrilintide 2.4 mg alone lowered systolic and diastolic blood pressure more than placebo, and more users reduced or stopped blood pressure medication (27.6% versus 18.8%) (Verma 2026, Novo Nordisk-funded). The effect likely follows weight loss. A meta-analysis reports a similar modest effect (Rao 2026), but all data come from one sponsor’s trials, and the effect was smaller than with semaglutide.
Magnitude: Systolic pressure 2.4 mm Hg lower than placebo (95% CI 0.8 to 4.1) and diastolic 1.3 mm Hg lower (95% CI 0.1 to 2.4) at 68 weeks (Verma 2026).
Blood-Sugar Control in Type 2 Diabetes
In the 68-week REIMAGINE 2 trial led by Buse, cagrilintide alone lowered HbA1c (glycated hemoglobin, a three-month blood sugar average) more than placebo in adults with type 2 diabetes on metformin (Buse 2026, Novo Nordisk-funded). A 32-week trial led by Frias, without a placebo arm, showed a fall about half that with semaglutide and no severe hypoglycemia (dangerously low blood sugar) (Frias 2023). A meta-analysis found no glucose benefit in people without diabetes (Rao 2026).
Magnitude: HbA1c 0.89 percentage points lower than placebo (95% CI 0.58 to 1.20) at 68 weeks (Buse 2026).
Low 🟩
No benefit is graded Low: each human outcome above comes from randomized controlled trials, and the remaining claims rest only on animal or mechanistic data or an unvalidated blood-fat marker.
Speculative 🟨
Triglyceride Lowering
In one placebo-controlled trial, pooled by a meta-analysis, cagrilintide lowered triglycerides (blood fats) and VLDL-C (very-low-density lipoprotein cholesterol) (Dutta 2024). Triglycerides are an unvalidated surrogate; no heart-event data exist.
Preferential Fat Loss with Lean-Mass Sparing
A review reports that in rodents amylin analogues cut fat more than matched food restriction, with cagrilintide sparing lean tissue (Alhazmi 2026). No human body-composition data exist; the basis is animal only.
Bone Preservation During Weight Loss
Calcitonin receptor activation slows bone breakdown, so cagrilintide might limit weight-loss bone loss, a review notes (Alhazmi 2026). The basis is mechanistic only; a human bone trial is recruiting (NCT07010432).
Alzheimer’s Disease Protection ⚠️ Conflicted
Amylin and pramlintide reduced brain amyloid in Alzheimer’s mice (Zhu 2015), yet amylin receptor blockers also improved memory in such mice (Soudy 2019). Net: animal data point both ways.
Benefit-Modifying Factors
- Genetic polymorphisms: No gene variant has been studied for cagrilintide response. Because it is not metabolized by CYP liver enzymes, common drug-metabolism variants are not expected to matter; variation in amylin-receptor components is untested.
- Baseline weight and HbA1c: Trials enrolled people with a BMI (body-mass index, weight in kg divided by height in metres squared) of 30 or more, or 27 or more with a weight-related condition. Effects in leaner adults are unknown; glucose benefit requires elevated HbA1c.
- Sex: About two-thirds of REDEFINE 1 participants were women (Verma 2026). No sex-specific results for cagrilintide alone have been published.
- Type 2 diabetes: People with type 2 diabetes lost 8.1% of body weight on cagrilintide at 32 weeks (Frias 2023). No trial has compared weight loss directly between people with and without diabetes.
- Age: Trial participants averaged about 47 years (Verma 2026). In adults over 65, preserving muscle and bone may matter more than additional weight loss, and no age-specific efficacy data exist.
Potential Risks & Side Effects
Safety data on cagrilintide alone come from about 1,000 treated people in Novo Nordisk-funded trials of up to 68 weeks, so rare or long-delayed harms cannot yet be excluded.
High 🟥 🟥 🟥
Gastrointestinal Adverse Events
Nausea, constipation, diarrhea and vomiting are the most common effects, mostly mild to moderate and concentrated during dose increases. They reflect slowed stomach emptying and hindbrain signaling. They were found in trials led by Lau (Lau 2021), Frias (Frias 2023) and Garvey (nausea caused 1.0% to stop versus 0.1% on placebo; Novo Nordisk press release, reprinted by Drugs.com). A meta-analysis found vomiting less frequent than with GLP-1 drugs (Dutta 2024). In REIMAGINE 2, any adverse event (gastrointestinal most common) affected 82.2% on cagrilintide versus 70.5% on placebo (Buse 2026).
Magnitude: At 2.4 mg over 26 weeks, nausea 32/102 versus 18/101 on placebo, constipation 17/102 versus 7/101, diarrhea 18/102 versus 9/101, vomiting 9/102 versus 3/101 (liraglutide 20/99) (NCT03856047).
Medium 🟥 🟥
Injection-Site Reactions
Redness, itching and local reactions at the injection site occurred with cagrilintide but not with placebo in the dose-finding trial (Lau 2021). They are usually mild and resolve, but are more common than with liraglutide. Evidence comes from one research group.
Magnitude: At 2.4 mg, injection-site reaction 12/102, erythema (redness) 7/102 and itching 7/102, versus 0/101 for each on placebo (NCT03856047).
Fatigue
Tiredness was reported more often with cagrilintide than placebo, rising with dose (Lau 2021). Lower food intake is the likely cause. A network meta-analysis found fatigue about three times as common (risk ratio 3.2; 92 more per 1,000 people over one year) with the cagrilintide-semaglutide combination (Nong 2026), which is indirect for cagrilintide alone.
Magnitude: 10/102 at 2.4 mg and 20/101 at 4.5 mg versus 3/101 on placebo over 26 weeks (NCT03856047).
Dizziness
Dizziness was more frequent with cagrilintide than placebo in the dose-finding trial (Lau 2021). Lower blood pressure and reduced food and fluid intake are plausible causes. With the semaglutide combination, hypotension (abnormally low blood pressure) was reported in 1.8% versus 0.4% on placebo (Verma 2026), which is indirect for cagrilintide alone.
Magnitude: 9/102 at 2.4 mg versus 3/101 on placebo over 26 weeks (NCT03856047).
Low 🟥
Serious Adverse Events ⚠️ Conflicted
A meta-analysis found more serious adverse events with cagrilintide than semaglutide (Ahmed 2026). Placebo comparison showed no excess (Lau 2021), and another meta-analysis found rates comparable (Dutta 2024). Net: no excess over placebo shown.
Magnitude: Risk ratio 1.83 versus semaglutide (95% CI 1.03 to 3.24) (Ahmed 2026); 3/102 at 2.4 mg versus 3/101 on placebo (NCT03856047).
Gallbladder Events
Rapid weight loss promotes gallstones. In the dose-finding trial, single cases of biliary colic (gallstone pain) and cholelithiasis (gallstones) occurred on cagrilintide and none on placebo (Lau 2021). Counts are too small to confirm a drug effect.
Magnitude: 1/102 biliary colic (1.2 mg) and 1/101 cholelithiasis (4.5 mg) versus 0/101 on placebo (NCT03856047).
Hypoglycemia with Insulin or Other Glucose-Lowering Drugs
Amylin lowers post-meal glucose, so adding it to insulin can cause hypoglycemia (dangerously low blood sugar); pramlintide carries a boxed warning for this (pramlintide FDA label). Evidence is indirect (different compound); with metformin, cagrilintide caused no severe hypoglycemia (Frias 2023).
Magnitude: Not quantified in available studies. No published trial has reported hypoglycemia rates for cagrilintide alone added to insulin or sulfonylureas (oral drugs that force insulin release).
Cancer Signal from Calcitonin Receptor Activation
Cagrilintide activates the calcitonin receptor. A review found that long-term salmon calcitonin, a calcitonin receptor drug, showed more cancers than placebo in most trials, prompting regulatory review (Overman 2013). This evidence is indirect (different compound); no cancer excess has been reported for cagrilintide.
Magnitude: Malignancy was more frequent in the salmon calcitonin arm in 15 of 18 placebo-controlled trials (Overman 2013); the literature reports no figure for cagrilintide.
Speculative 🟨
Aspiration (Inhaling Stomach Contents) Risk During Anesthesia
Amylin drugs slow gastric emptying (pramlintide FDA label), which could leave food in the stomach during sedation. The basis is mechanistic only; no cagrilintide case has been reported.
Muscle and Bone Loss During Weight Loss
All substantial weight loss removes some lean mass and bone. No human body-composition or bone data for cagrilintide alone exist; muscle and bone trials are recruiting (NCT07527195, NCT07010432). The basis is mechanistic only.
Risk-Modifying Factors
- Genetic polymorphisms: No pharmacogenetic variant is known to change cagrilintide exposure or side effects; it does not use CYP liver enzymes. Gallstone-predisposing variants (e.g., in ABCG8, a gene encoding a liver cholesterol transporter) may plausibly raise gallbladder risk during rapid weight loss.
- Baseline glucose and blood pressure: Cagrilintide lowers blood pressure and glucose (Verma 2026; Frias 2023), so people near low-normal blood pressure or using glucose-lowering drugs may plausibly face more dizziness or hypoglycemia; no trial has examined this.
- Sex: No sex-specific safety analyses have been published for cagrilintide alone. Effects on pregnancy are unknown, which is relevant for women of reproductive age.
- Pre-existing conditions: Gastroparesis (delayed stomach emptying), gallstones, diabetes treated with insulin or sulfonylureas and eating disorders raise risk. Kidney or liver impairment did not change drug levels (Nielsen 2026).
- Age: Older adults face greater consequences from lean-mass loss, dehydration and dizziness-related falls. Pharmacokinetic (drug-level) studies enrolling people averaging 58–70 years found similar exposure across kidney and liver function groups (Nielsen 2026); age itself was not compared.
Key Interactions & Contraindications
Documented interactions:
- Semaglutide (a GLP-1 drug): No pharmacokinetic interaction found; cagrilintide did not change semaglutide exposure (Enebo 2021). Together they double gastrointestinal adverse events (79.6% versus 39.9% on placebo; Garvey 2025); slower titration mitigates this.
- Antihypertensives (blood pressure drugs: lisinopril, amlodipine, losartan): Additive blood pressure lowering; 27.6% of cagrilintide users reduced or stopped them versus 18.8% on placebo (Verma 2026). Home blood pressure checks guide dose reduction.
Theoretical interactions (inferred from mechanism, not studied in humans):
- QT-prolonging drugs (moxifloxacin, citalopram): Added heart-rhythm risk not expected, inferred from cagrilintide alone causing no clinically relevant QTc (heart-rate-corrected electrical recovery time) prolongation (Gabe 2024); the pairing was not studied. Electrocardiogram checks per the partner drug’s label mitigate.
- Insulin and sulfonylureas (glipizide, glimepiride): Hypoglycemia, inferred from additive glucose lowering by amylin-receptor activation; not studied with cagrilintide. Reducing insulin or sulfonylurea doses at initiation and frequent glucose checks mitigate it.
- Oral drugs needing rapid onset (acetaminophen, antibiotics such as amoxicillin, oral contraceptives such as levonorgestrel-ethinylestradiol): Delayed or blunted absorption, inferred from slowed gastric emptying. Watching for reduced effect, and backup contraception during dose escalation, mitigate it.
- Narrow-range oral drugs (warfarin, levothyroxine): Altered absorption, inferred from slowed gastric emptying; a warfarin study with the combination (NCT06289504) has posted no results. Extra INR (clotting test) or thyroid checks during titration mitigate.
- Gut-slowing drugs (atropine, oxybutynin, opioids such as oxycodone, loperamide): Additive constipation and delayed emptying, inferred from amylin’s effect on gastric emptying. Minimizing use and monitoring bowel habits mitigate.
- Glucose-lowering supplements (berberine, chromium, cinnamon extract): Additive glucose lowering, mainly relevant with insulin or sulfonylureas. Glucose monitoring mitigates.
- Blood-pressure-lowering supplements (beetroot nitrate, garlic extract, magnesium): Additive blood pressure lowering may cause dizziness. Home blood pressure checks mitigate.
- Fiber appetite supplements (glucomannan, psyllium): Additive fullness and slowed emptying, inferred from mechanism; may worsen nausea or bloating. Spacing and lower doses mitigate.
- Alcohol: Additive hypoglycemia risk with insulin and dehydration risk with vomiting, inferred from mechanism. Limiting intake mitigates.
Populations who should avoid Cagrilintide:
- Pregnancy, planned pregnancy or breastfeeding: Inferred from the lack of any human data and the inappropriateness of weight loss in pregnancy; no human data.
- Confirmed gastroparesis: Contraindicated for the related amylin drug pramlintide (pramlintide FDA label); inferred for cagrilintide from shared slowing of stomach emptying.
- Hypoglycemia unawareness (inability to sense falling blood sugar) on insulin: Contraindicated for pramlintide (pramlintide FDA label); inferred for cagrilintide from shared glucose lowering.
- Underweight (BMI under 18.5) or history of anorexia nervosa or bulimia: Inferred from appetite suppression and weight loss; no human data.
- Under 18 years: Inferred from appetite suppression during growth, when nutrient needs are high; pediatric trials are ongoing (NCT07253285); no human data.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Slow dose titration: Stepping up from 0.25 mg every 4 weeks to 2.4 mg over 16 weeks, as in trials pooled by a meta-analysis (Dutta 2024), limits nausea and vomiting; persistent symptoms warrant holding a step 4 more weeks.
- Small, low-fat meals: Eating smaller portions and stopping at first fullness limits nausea and bloating caused by slowed stomach emptying.
- Hydration of at least 2 litres daily: Prevents dehydration and dizziness from reduced intake, vomiting or diarrhea; persistent vomiting over 24 hours warrants medical review.
- Insulin reduction: Cutting mealtime insulin by 50% when starting an amylin drug, as the pramlintide label specifies (pramlintide FDA label), prevents hypoglycemia.
- Blood pressure review: Home readings twice weekly during titration; reviewing antihypertensives if systolic pressure falls below 110 mm Hg or dizziness on standing occurs, preventing low blood pressure and falls.
- Injection-site rotation: Rotating abdomen, thigh and upper arm weekly reduces local redness and itching.
- Protein and resistance training: About 1.2–1.6 g protein per kg body weight daily and resistance training 2–3 times weekly limit lean-mass and bone loss.
- Gallbladder vigilance: Persistent right-upper abdominal pain, fever or yellowing skin prompts evaluation for gallstones or inflammation.
- Regulated supply only: Using cagrilintide only within clinical trials or after regulatory approval avoids contamination and dosing errors from unregulated products.
Therapeutic Protocol
Timing, titration steps and other parameters without a citation reflect common practice.
- Standard trial dose: 2.4 mg injected under the skin once weekly, the dose used in phase 3 trials (Garvey 2025).
- Alternative higher dose: 4.5 mg weekly produced the most weight loss in dose-finding but more fatigue and injection-site reactions (Lau 2021).
- Titration schedules: 0.25, 0.5, 1.0, 1.7, then 2.4 mg at 4-week steps; the dose-finding trial instead started at 0.6 mg, doubling every 2 weeks (both summarized in a meta-analysis, Dutta 2024).
- Practitioner view: Peter Attia argues for waiting for the approved product rather than using online “research” cagrilintide (Attia AMA #83). No physician-published off-label protocol exists.
- Time of day: Any time, on the same weekday each week, with or without food; evening injection may let early nausea pass during sleep.
- Half-life: 159–195 hours (Enebo 2021), giving steady levels after about 4–5 weeks at a fixed dose.
- Single versus split dose: A single weekly injection; splitting is unnecessary given the long half-life and has not been studied.
- Genetic polymorphisms: No variant (e.g., APOE4, a gene variant raising Alzheimer’s risk, or CYP genes) is known to change dosing; cagrilintide bypasses CYP metabolism.
- Sex differences: No sex-specific dosing; trials used the same doses for women and men.
- Age: No age-based dose adjustment has been studied; kidney and liver impairment studies in people averaging 58–70 years required none (Nielsen 2026). Older adults may stay at lower steps longer to protect muscle and limit dizziness.
- Baseline biomarkers: Trials enrolled BMI 30 or more, or 27 or more with a weight-related condition; glucose benefit depends on elevated HbA1c.
- Pre-existing conditions: Diabetes on insulin or sulfonylureas requires dose reduction of those drugs; kidney or liver impairment needs no cagrilintide adjustment (Nielsen 2026).
Discontinuation & Cycling
- Long-term use: Cagrilintide is developed as continuous, long-term weight-management therapy; benefits are expected to last only while it is taken.
- Weight regain: No cagrilintide stop study exists; after stopping semaglutide, people regained two-thirds of lost weight within a year (Wilding 2022), indirect evidence of likely regain.
- Withdrawal effects: No withdrawal syndrome is known; appetite returns gradually as the drug clears over about 5 weeks.
- Tapering: No taper protocol has been studied; stepping down through lower doses over 4–8 weeks may soften the return of appetite.
- Missed doses and restart: After 2 or more missed weeks, restarting at a lower step reduces nausea.
- Cycling: No evidence supports cycling; intermittent use is expected to cause weight fluctuation and repeated titration side effects.
Sourcing and Quality
- No approved product: Cagrilintide is an investigational drug (Novo Nordisk press release, reprinted by Drugs.com) and an unapproved new drug in the U.S. (FDA warning letter); legitimate supply exists only within trials, using pen-injectors (NCT03856047).
- Research-peptide market: Online vendors sell cagrilintide labelled “research use only”; the FDA treats these as unapproved new drugs (FDA warning letter).
- Purity and identity risks: Unregulated vials may be underdosed, degraded, mislabelled or contaminated with bacterial endotoxin (fever-causing bacterial cell-wall material); amylin’s tendency to clump into fibrils made cagrilintide a challenging molecule to design (Kruse 2021).
- What to look for: Only a regulated product from Novo Nordisk, the sole developer, offers verified identity, sterility and dose; vendor certificates of analysis cannot be independently verified.
- Compounding pharmacies: No reputable compounding source exists; no approved cagrilintide product or quality standard exists against which a compounded version could be checked.
Practical Considerations
- Time to effect: Weight loss begins during the 16-week titration and continued through 26 weeks in dose-finding (Lau 2021) and 68 weeks in phase 3 (Garvey 2025).
- Regulatory status: Cagrilintide alone is an unapproved new drug (FDA warning letter); the cagrilintide-semaglutide combination was submitted to the U.S. Food and Drug Administration in December 2025 (Novo Nordisk press release).
- Common pitfall – fast titration: Jumping to full dose causes most of the nausea and early stopping.
- Common pitfall – unregulated vials: Self-sourced “research” products add contamination and dosing risk absent from trials.
- Common pitfall – ignoring muscle: Weight loss without protein and resistance training sacrifices lean mass.
- Cost and access: Not legally available outside trials. Once marketed, cost will likely mirror other branded weight-loss injections; insurers and national health systems have a financial incentive to restrict coverage or favor cheaper alternatives, which can bias coverage guidelines.
Interaction with Foundational Habits
- Sleep: Indirect, potentially improving. No cagrilintide sleep data exist; weight loss generally eases obstructive sleep apnea (breathing pauses from airway collapse during sleep). Evening injection may let early nausea pass during sleep; late large meals worsen reflux when stomach emptying is slowed.
- Nutrition: Direct. Reduced appetite risks low protein, fiber and micronutrient intake. Prioritizing protein at each meal, small portions and limiting high-fat meals that worsen nausea are practical considerations. Alcohol intake may also fall, a question under study in alcohol-related liver disease (NCT06409130).
- Exercise: Indirect, potentially blunting. Calorie deficit can blunt strength and muscle gain; resistance training 2–3 times weekly counters lean loss. Fatigue and dizziness may limit hard sessions during titration; fuelling before training helps. A muscle study is recruiting (NCT07527195).
- Stress management: None known. No cortisol or stress-response data exist for cagrilintide. Stress-driven eating may lessen through stronger fullness signaling, but this has not been studied.
Monitoring Protocol & Defining Success
Before starting, baseline testing establishes the reference points against which change is judged: body weight, waist circumference and home blood pressure, plus HbA1c, fasting glucose and kidney function, and ideally a body-composition scan (DXA, dual-energy X-ray absorptiometry, measuring fat, lean mass and bone). People on insulin or sulfonylureas also set up home glucose monitoring.
Ongoing monitoring runs at 4, 8, 12 and 16 weeks during titration, then every 3 months for the first year and every 6–12 months thereafter. Weight and blood pressure are checked weekly at home during titration. HbA1c and kidney function are repeated every 3 months in people with diabetes and every 6–12 months otherwise. A repeat body-composition scan after 6–12 months shows whether lean mass is being preserved. Success means steady weight and waist reduction with stable or improved lean mass and no persistent side effects.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Body weight and waist circumference | No established target; track percentage change from own baseline | Expected to change (main effect) | Same scale, morning, after voiding; waist at navel level |
| Blood pressure | Below 120/80 mm Hg, “normal” category of the 2017 ACC/AHA guideline | Expected to change; safety check for low pressure | ACC/AHA: American College of Cardiology/American Heart Association. Source: Whelton 2018; conventional reference range is the same below 120/80 mm Hg. Guideline authors’ members treat hypertension, a revenue interest in its definition. Seated, rested, home readings |
| HbA1c | 4.0–5.6% (standard reference range) | Expected to change in diabetes or prediabetes | HbA1c (glycated hemoglobin) reflects 3-month glucose; no fasting needed |
| Fasting glucose | 70–99 mg/dL (standard reference range) | Safety check for hypoglycemia with insulin or sulfonylureas | Fasting at least 8 hours; pair with HbA1c |
| eGFR | 60 mL/min/1.73 m² or higher (standard reference range) | Safety check for dehydration from vomiting or diarrhea | eGFR (estimated glomerular filtration rate) from serum creatinine; recheck after any severe gastrointestinal episode |
| Lean mass by DXA | No established target; track change from own baseline | Safety check for muscle loss | DXA (dual-energy X-ray absorptiometry) also shows fat mass and bone density |
Qualitative markers:
- Appetite and fullness after meals
- Frequency and severity of nausea, constipation or diarrhea
- Energy levels and fatigue
- Dizziness on standing
- Injection-site redness or itching
- Strength and exercise capacity
Emerging Research
- RENEW 1 (phase 3, monotherapy): Cagrilintide versus placebo for weight in 300 adults with overweight or obesity; active, not recruiting, completion 2027 (NCT07220642). A positive result would confirm monotherapy weight loss outside REDEFINE 1; a null result would weaken the High grade.
- RENEW 2 (phase 3, diabetes): Cagrilintide versus placebo for weight in 330 adults with type 2 diabetes; completion 2027 (NCT07220759). A positive result would support benefit in diabetes; a null result would limit cagrilintide to people without diabetes.
- RENEW 4 (phase 3, new formulation): Compares two cagrilintide presentations with placebo in 285 adults; recruiting (NCT07745504). Positive results enable a marketed device; a null result would change only formulation choice.
- RAMBO bone trial: Cagrilintide, semaglutide or placebo in 144 postmenopausal women, primary endpoint hip bone density; recruiting, completion 2028 (NCT07010432). A positive result would lift bone preservation above Speculative; a null result would remove it.
- RASMUS muscle trial: Skeletal-muscle insulin sensitivity and composition in 100 participants; recruiting (NCT07527195). Positive results would support muscle sparing; null results would strengthen the lean-loss concern.
- GLP-1-intolerance trial: Tolerability of cagrilintide in 114 people who stopped GLP-1 drugs for stomach effects; recruiting (NCT07607587). A positive result would define a niche; a null result would undercut the tolerability argument.
- REDEFINE 3 (combination outcomes): Cagrilintide-semaglutide versus placebo on heart attack, stroke and cardiovascular death in 7,101 people with heart disease; completion 2027 (NCT05669755). A positive result would raise interest in cagrilintide’s contribution; a null or harmful result would weaken the case for cagrilintide too.
- Completed, results pending: Kidney trial in type 2 diabetes with a cagrilintide-alone arm (completed 2025, no results posted; NCT06131372) and alcohol-related liver disease trial (completed 2026, no results posted; NCT06409130).
- Completed REIMAGINE 2 arm: The phase 3 diabetes trial (completed, published) randomized 152 people to cagrilintide alone; versus placebo it lowered HbA1c by 0.89 percentage points and weight by 7.0%, with adverse events in 82.2% versus 70.5% (Buse 2026).
- Brain and Alzheimer’s research: Conflicting animal data on amylin agonists (Zhu 2015) and antagonists (Soudy 2019) need human trials.
- Competing amylin drugs: Newer amylin drugs such as the selective agonist eloralintide (phase 3) and the dual agonist petrelintide (phase 2) are in development, a review reports (Alhazmi 2026); if selective agents match efficacy without calcitonin activity, cagrilintide’s calcitonin-related risks become harder to justify.
Conclusion
Cagrilintide is an experimental once-weekly injection that copies amylin, a meal-ending hormone from the pancreas. On its own it produces meaningful, well-replicated weight loss in adults with excess weight, roughly comparable to established weight-loss injections in head-to-head comparisons. Smaller effects on blood pressure and, in people with diabetes, blood sugar are reasonably supported. A fall in blood fats has not been tied to fewer heart problems, and claims about muscle sparing, bone protection or brain health come only from animal work or theory.
Its side effects are mostly stomach-related, such as nausea and constipation, and appear to cause less vomiting than the popular appetite-suppressing injections. Injection-site reactions, tiredness and dizziness are also more common than with placebo. Open questions remain about serious events, a cancer signal seen with a related bone drug, and low blood sugar when combined with insulin.
The evidence base is short-term and almost entirely funded by the company developing the drug, which has a direct financial stake in it. No study has tested whether it extends healthy life or prevents disease events. Because it is unapproved, the product sold online as a “research peptide” carries added uncertainty about what is actually in the vial. For health-focused adults with excess weight, cagrilintide is a promising but still unproven option whose long-term value remains uncertain.